Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Emergent Biosolutions Inc. EBS

Healthcare — Drug Manufacturers Specialty & Generic

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
1.42
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 2 1 — — — 2 3 — 1 — —
Insider Ownership
6.59%

Capital & Financial Ratios

Market Cap
359.94
Revenue
770.20
Net Income
(176.80)
Free Cash Flow
86.10
Net Debt
440.90
Current Ratio
5.42
Debt/Equity
1.70
P/E ratio
0.00
P/S ratio
0.46
P/B ratio
1.03
Past 5Y EPS Growth
—
This Y EPS Growth
(76.50%)
Next Y EPS Growth
190.99%
Next 5Y EPS Growth
0.83%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
0.79%
total individual payouts
2025 ‡‡‡
2024 ‡‡‡‡
2023 ‡‡‡‡
2022 ‡‡‡‡
2021 ‡‡‡‡
2020 ‡‡‡‡
2019 ‡‡‡‡
2018 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 111.70 105.60 209.10 140.90
Receivables 191.00 154.50 84.20 190.00
Inventory 328.90 311.70 343.40 303.60
Other — — — 6.10
679.50 598.70 662.50 666.00
2023 2024 2025 Q'26
Payables 112.20 60.90 55.60 50.20
ST’ Debt 413.70 — — —
Other 32.70 21.90 15.80 9.90
651.30 162.40 132.20 122.80
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 156.10 234.30 — —
—
’25 222.20 140.90 231.10 148.70
742.90
’24 300.40 254.70 293.80 194.70
1,043.60
’23 164.30 337.90 270.50 276.60
1,049.30
’22 307.50 242.70 239.90 327.40
1,117.50
’21 343.00 397.50 329.00 704.10
1,773.60
’20 192.50 394.70 385.20 583.00
1,555.40
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (33.80) 56.10 — —
—
’25 (11.20) 106.40 (2.30) 77.70
170.60
’24 (62.60) 47.50 153.70 (79.90)
58.70
’23 (184.00) (114.40) 60.00 32.10
(206.30)
’22 (37.30) (15.60) (74.00) 92.80
(34.10)
’21 5.10 (29.70) 16.70 328.10
320.20
’20 57.80 127.90 105.20 245.10
536.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (36.20) 54.20 — —
—
’25 23.30 103.60 (5.70) 73.80
195.00
’24 (73.40) 42.90 155.50 (81.30)
43.70
’23 (199.10) (126.90) 47.40 20.70
(257.90)
’22 (69.50) (47.70) (101.90) 47.40
(171.70)
’21 (51.00) (96.70) (38.50) 282.30
96.10
’20 33.60 92.80 59.50 209.10
395.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.07 (3.49) — —
—
’25 1.19 (0.22) 0.91 (1.04)
0.93
’24 0.17 (5.38) 2.06 (0.58)
(3.60)
’23 (3.65) (5.15) (5.08) (0.95)
(14.85)
’22 (0.07) (1.13) (1.52) (1.76)
(4.47)
’21 1.28 0.09 (0.61) 3.50
4.27
’20 (0.24) 1.73 0.73 3.44
5.67

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.61 1.81 1.42 4.02 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.28 16.66 15.10 13.41 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,500 1,600 900 900 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.45 0.66 1.16 0.83 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,117.50 1,049.30 1,043.60 742.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.98% 32.77% 34.72% 56.09% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (219.00) (731.20) (142.90) 82.80 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.60%) (69.68%) (13.69%) 11.15% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (211.60) (760.50) (190.60) 52.60 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 154.10 364.60 116.20 105.60 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.31 20.49 19.69 13.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ (4.47) (14.85) (3.60) 0.98 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.68) (4.03) 1.11 3.19 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.75) (1.01) (0.28) 0.46 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.43) (5.04) 0.82 3.64 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.70 12.68 9.11 9.77 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 50.10 51.20 53.00 53.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 13.01 ‡‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.54 0.13 0.49 0.89 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.43 0.20 1.05 1.27 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.22 0.84 1.02 1.38 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.11) (3.42) 24.38 5.26 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34.10) (206.30) 58.70 170.60 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (137.60) (51.60) (15.00) 24.40 ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (171.70) (257.90) 43.70 195.00 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.50) 28.20 436.30 530.30 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,405.80 860.20 663.70 572.10 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 763.20 748.50 558.10 363.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,387.70 649.30 482.80 522.60 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.91%) (30.48%) (11.86%) 3.88% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.94%) (32.48%) (6.53%) 7.06% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.08%) (74.67%) (33.67%) 10.46% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Emergent BioSolutions (EBS) rode the COVID-19 wave to explosive growth, with revenues tripling to $1.77 billion in 2021 amid vaccine manufacturing deals, echoing its BioThrax surge post-2001 anthrax attacks. Yet, a 2021 FDA halt on its Baltimore facility due to contamination wiped out hundreds of millions in revenue, triggering margin collapses from 74% to 35%, massive losses exceeding $1 billion cumulatively since 2022, and a 64% workforce slash. The stock cratered from $138 peaks to $1.42 lows, now trading at fire-sale valuations like 0.13x PS and near 1x PB, amid persistent debt at $664 million and insider selling outpacing a lone CEO buy.

Recent restructuring shines through: revenue per employee rebounded to $1.16 million, operating cash flow flipped positive at $59 million in 2024, and a $450 million contract extension bolsters biodefense runway with products like Cyfendus. Analyst forecasts signal volatility—revenues dipping to $809 million in 2025 before rebounding 43% in 2026—tied to government stockpiling and plague vaccine approvals, with EPS swinging wildly but potentially turning positive.

This high-beta turnaround mirrors biopharma busts like VaxGen’s collapse, yet cheap multiples and historical recoveries on mandates suggest 20-38% upside if execution holds and debt ebbs. Debt leverage, DOJ probes, and lumpy contracts demand caution, positioning EBS as a speculative bet on America’s biothreat preparedness.

Read full commentary →

Emergent Biosolutions Inc. (EBS) Latest News

News by impact score

Fine-tune

31 Aug

3 , 7:55 AM
Emergent BioSolutions Inc. received a standing offer from the Government of Canada to supply NARCAN Nasal Spray to federal, provincial and territorial governments and agencies. Canadian government standing offer expands NARCAN distribution channels and supports incremental revenue.

12 Aug

4 transcript www.fool.com, 6:13 PM
Emergent BioSolutions (EBS) released its Q2 2026 earnings call transcript. Earnings call transcript outlines financial results and outlook that can drive material shifts in valuation and sentiment.

8 Aug

3 transcript www.marketbeat.com, 1:03 AM
Emergent Biosolutions Q2 earnings call covered financial results, operational updates, and strategic outlook for the period. Quarterly earnings updates typically influence near-term sentiment and valuations but rarely shift long-term company trajectory.

6 Aug

3 transcript app.moby.co, 8:30 AM
Emergent BioSolutions Inc. held its Q2 2026 earnings call covering financial results, operational updates and forward outlook. Quarterly earnings provide financial and outlook details that moderately influence near-term sentiment and performance.

5 Aug

3 , 4:07 PM
Emergent BioSolutions commits to cross-sector collaboration against biological threats in an evolving global security environment. Commitment to collaborations may moderately expand biodefense opportunities without fundamentally altering company trajectory.

3 , 4:07 PM
Emergent BioSolutions Inc. released its second quarter 2026 financial results. Quarterly earnings releases update financial performance and can moderately shift investor sentiment and near-term stock movement.

29 Jun

3 , 9:13 AM
Emergent BioSolutions secures $52.7 million U.S. government contract modification for ACAM2000 smallpox and mpox vaccine. Contract modification delivers measurable revenue for core vaccine product.

28 May

3 GlobeNewswire, 4:01 PM
Emergent BioSolutions receives $64.5 million contract modification for BAT botulism antitoxin to support U.S. biodefense strategy. Contract modification adds revenue for existing product but does not alter core operations or long-term trajectory.

20 May

4 Insider Monkey, 4:43 PM
Emergent BioSolutions Inc. (EBS) gains attention after ACAM2000 receives broader public health authorization. Broader authorization for ACAM2000 expands market opportunities and revenue potential for Emergent BioSolutions' core biodefense vaccine.

2 May

4 www.marketbeat.com, 10:29 AM
Emergent BioSolutions presented a turnaround update at its 2026 Annual Meeting, where all proposals received shareholder approval. Turnaround update shared at annual meeting with all proposals approved represents a major strategic milestone boosting recovery prospects and investor sentiment.

1 May

4 GuruFocus.com, 3:19 AM
Emergent BioSolutions Inc. (EBS) reported strong revenue growth and key strategic advancements in its Q1 2026 earnings call. Strong Q1 revenue signals major financial improvement and strategic positioning to enhance EBS market performance.

3 app.moby.co, 8:30 AM
Emergent BioSolutions Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 earnings summary affects financial performance and investor sentiment but balanced by market factors.

3 www.marketbeat.com, 7:18 AM
Emergent BioSolutions Q1 revenue fell 40% to $146.9 million from $244.6 million year-ago due to lower contract manufacturing. Net loss narrowed to $50.4 million from $102.5 million. Narcan sales grew 8% to $40.8 million amid opioid initiatives. Company advanced vaccines for chikungunya and Ebola, reaffirmed full-year revenue guidance of $730-800 million. Revenue dropped sharply year-over-year but losses narrowed and full-year guidance held steady, pointing to moderate effects on financial trajectory.

30 Apr

4 GlobeNewswire, 7:55 AM
Emergent BioSolutions Inc. received approval from the Singapore Health Sciences Authority for an expanded indication of ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include Mpox. Regulatory approval expands ACAM2000's addressable market to Mpox in Singapore, enhancing revenue potential and market position.

3 GlobeNewswire, 4:30 PM
Emergent BioSolutions Inc. (EBS) reported first quarter 2026 financial results. Q1 financial results affect key financial performance metrics and investor sentiment for EBS.

29 Apr

4 GlobeNewswire, 7:35 AM
Emergent BioSolutions Inc. (EBS) secured a long-term strategic manufacturing contract with SAB Biotherapeutics to produce SAB-142, a candidate therapy for Type 1 diabetes. Long-term manufacturing contract provides stable revenue, expands EBS's biomanufacturing portfolio into diabetes therapeutics, and bolsters strategic partnerships.

28 Apr

4 GlobeNewswire, 8:01 AM
Emergent BioSolutions and Substipharm Biologics announced a strategic manufacturing partnership to support production of the Japanese Encephalitis Vaccine in the United States. Strategic partnership expands EBS manufacturing capacity for a critical vaccine, enhancing operational efficiency and market positioning.

23 Apr

4 Simply Wall St., 6:05 AM
Emergent BioSolutions (EBS) earnings miss triggers shifting narrative, highlighting operational challenges, contract losses, and cautious outlook amid revenue declines and margin pressures. Earnings miss and narrative shift signal major impacts on financials, contracts, and investor sentiment, altering EBS trajectory.

16 Apr

4 GlobeNewswire, 4:05 PM
Emergent BioSolutions refinanced its term loan, amended its asset-backed loan facility, and increased financial flexibility. Refinancing debt and amending facilities bolsters balance sheet strength and liquidity, significantly aiding financial stability and market perception.

9 Apr

3 GlobeNewswire, 4:25 PM
Emergent BioSolutions partners with British Columbia to supply NARCAN Nasal Spray for the launch of the province's expanded Take Home Naloxone Program. Partnership secures NARCAN supply contract for British Columbia's expanded naloxone program, potentially boosting regional sales and revenue amid opioid crisis response.

3 app.moby.co, 2:34 PM
McKinsey will contribute $125 million to Purdue Pharma's $7 billion bankruptcy settlement over the opioid crisis, potentially boosting funds for naloxone distribution benefiting Emergent BioSolutions' Narcan production. Additional settlement funds increase resources for opioid abatement programs, moderately enhancing demand for EBS's Narcan overdose reversal product.

7 Apr

4 GlobeNewswire, 8:05 AM
Emergent BioSolutions Inc. (EBS) launches new NARCAN Nasal Spray carrying case and multipacks alongside college campus outreach to expand opioid overdose preparedness. Launching NARCAN accessories and targeted outreach significantly boosts product accessibility, sales potential, and positioning in the opioid reversal market.

25 Mar

4 GlobeNewswire, 4:15 PM
Emergent BioSolutions Inc. (EBS) secures over $60 million in new contract awards from the U.S. Government and orders from an international government partner for smallpox medical countermeasures. Over $60 million in government contracts for core smallpox countermeasures directly boosts EBS revenue and reinforces its biodefense market position.

10 Mar

4 Simply Wall St., 3:16 PM
Analysts reset Emergent BioSolutions (EBS) price target to $12, prompting a shift in investment narrative amid evolving company prospects and market dynamics. Price target reset to $12 indicates major shift in investor sentiment and potential trajectory alteration for EBS.

28 Feb

3 www.marketbeat.com, 1:07 AM
Emergent BioSolutions Q4 earnings call highlighted revenue decline to $146.8 million from $260.5 million year-over-year, net loss of $36.6 million, reaffirmed 2024 guidance, announced leadership changes, and progress on new biodefense contracts amid ongoing operational improvements. Q4 results show financial challenges balanced by strategic updates and guidance, moderately influencing financial performance and investor sentiment.

27 Feb

4 GuruFocus.com, 12:04 AM
Emergent BioSolutions Inc. (EBS) reported strategic gains in its Q4 2025 earnings call, offsetting revenue pressures through key operational advancements and future pipeline progress. Strategic gains in Q4 2025 earnings offset revenue challenges, signaling major shifts in operations and investor outlook.

26 Feb

4 GlobeNewswire, 4:01 PM
Emergent BioSolutions Inc. (EBS) announced approximately $140 million in contract awards from the Government of Canada to strengthen the nation's health preparedness leadership. $140 million in government contracts delivers significant revenue and bolsters EBS's strategic position in public health solutions.

3 Associated Press Finance, 4:58 PM
Emergent Biosolutions Inc. (EBS) released its Q4 earnings snapshot. Q4 earnings snapshots affect financial performance and market sentiment without fundamentally altering long-term trajectory.

3 GlobeNewswire, 4:05 PM
Emergent BioSolutions Inc. (EBS) reported fourth quarter and full-year 2025 financial results. Quarterly and annual financial results directly influence Emergent BioSolutions' financial performance and investor sentiment.

3 GlobeNewswireMT NewswiresMT NewswiresMT NewswiresMT Newswires, 4:01 PM
Emergent BioSolutions Inc. (EBS) announced a new $50 million stock repurchase program to buy back shares, signaling confidence in its future and aiming to enhance shareholder value. $50 million stock repurchase signals management confidence and may modestly boost EPS and share price without fundamentally altering long-term trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us